Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    19332717 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas
Condition: Chondrosarcoma
Interventions: Drug: Everolimus 2.5 mg/day;   Drug: Everolimus 10 mg/day
2 Active, not recruiting 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Drug: Dovitinib

Indicates status has not been verified in more than two years